Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Net Cash Flow (2020 - 2025)

Bolt Biotherapeutics' Net Cash Flow history spans 6 years, with the latest figure at $8.2 million for Q3 2025.

  • For Q3 2025, Net Cash Flow rose 157.0% year-over-year to $8.2 million; the TTM value through Sep 2025 reached $8.4 million, up 3815.42%, while the annual FY2024 figure was -$3.6 million, 304.13% down from the prior year.
  • Net Cash Flow for Q3 2025 was $8.2 million at Bolt Biotherapeutics, up from $1.2 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $89.9 million in Q1 2021 and bottomed at -$37.2 million in Q2 2021.
  • The 5-year median for Net Cash Flow is $1.2 million (2025), against an average of $645473.7.
  • The largest annual shift saw Net Cash Flow surged 487.47% in 2021 before it tumbled 231.45% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at $3.7 million in 2021, then crashed by 136.77% to -$1.4 million in 2022, then skyrocketed by 220.17% to $1.6 million in 2023, then crashed by 231.45% to -$2.2 million in 2024, then surged by 475.84% to $8.2 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Net Cash Flow are $8.2 million (Q3 2025), $1.2 million (Q2 2025), and $1.2 million (Q1 2025).